Interesting facts
Interesting Facts about 4-[(4-butyl-3,5-dioxo-1,2-diphenyl-pyrazolidin-4-yl)methoxy]-4-oxo-butanoic acid
4-[(4-butyl-3,5-dioxo-1,2-diphenyl-pyrazolidin-4-yl)methoxy]-4-oxo-butanoic acid is a compound that showcases the fascinating complexity of organic chemistry. Below are a few intriguing aspects of this unique compound:
- Versatile Functionality: This molecule contains multiple functional groups, which suggests that it could exhibit various biological activities. The presence of both the pyrazolidin ring and the butanoic acid moiety indicates potential pharmacological significance.
- Structure-Activity Relationship: The intricate structure of this compound allows chemists to explore how modifications can affect its reactivity and interactions with biological targets, making it a subject of interest in medicinal chemistry.
- Synthetic Pathways: The synthesis of such complex molecules often involves several steps and can be a rich field for research and development in synthetic organic chemistry. Learning about these pathways offers valuable insights into advanced chemical techniques.
- Potential Applications: Compounds like this have potential applications in drug discovery and development, particularly in treating diseases where the modulation of specific biological pathways is required.
- Research Interest: The compound may also be relevant in studies related to the dioxo-pyrazolidine framework, which has been investigated in various therapeutic areas.
In conclusion, 4-[(4-butyl-3,5-dioxo-1,2-diphenyl-pyrazolidin-4-yl)methoxy]-4-oxo-butanoic acid serves as a prime example of how intricate molecular structures can lead to significant implications in both theoretical and applied chemistry. As such, it invites further research and exploration.
Synonyms
suxibuzone
27470-51-5
Calibene
Suxibuzona
Flogos
Suxibuzonum
Solurol
Flamilon
Aflogan
Alfide
4-Hydroxymethylbutazolidine hemisuccinate
AE-17
4-((4-Butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy)-4-oxobutanoic acid
Suxibuzonum [INN-Latin]
Suxibuzona [INN-Spanish]
CHEBI:32173
4-Butyl-4-hydroxymethyl-1,2-diphenyl-3,5-pyrazolidinedione hydrogen succinate
AE 17
4-[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid
EINECS 248-477-6
86TDZ5WP2B
Suxibuzone [INN:BAN:JAN]
NSC-757866
BRN 0904563
DTXSID6021296
SUXIBUZONE [INN]
SUXIBUZONE [JAN]
4-BUTYL-4-[HYDROXYMETHYL]-1,2-DIPHENYL-3,5-PYRAZOLIDINEDIONE HYDROGEN SUCCINATE [ESTER]
SUXIBUZONE [MART.]
SUXIBUZONE [WHO-DD]
4-Butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione hydrogen succinate (ester)
Succinic acid, monoester with 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione
DTXCID601296
SUXIBUZONE [EP IMPURITY]
SUXIBUZONE [EP MONOGRAPH]
3-((4-Butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methoxycarbonyl)propionsaeure
4-Butyl-4-(beta-carboxypropionyl-oxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione
3,5-Pyrazolidinedione, 4-butyl-4-(hydroxymethyl)-1,2-diphenyl-, hydrogen succinate (ester)
NSC 757866
NCGC00016799-01
CAS-27470-51-5
Suxibuzonum (INN-Latin)
Suxibuzona (INN-Spanish)
SUXIBUZONE (MART.)
Butanedioic acid, mono((4-butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl) ester
SUXIBUZONE (EP IMPURITY)
SUXIBUZONE (EP MONOGRAPH)
Butanedioic acid, mono[(4-butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl] ester
SR-01000841241
UNII-86TDZ5WP2B
Suxibuzon
Suxibuzone; 4-[(4-Butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid
Prestwick_113
Suxibuzone (Standard)
Spectrum_000321
Suxibuzone (JAN/INN)
Prestwick0_000658
Prestwick1_000658
Prestwick2_000658
Prestwick3_000658
Spectrum2_000966
Spectrum3_000664
Spectrum4_000433
Spectrum5_001113
Epitope ID:124941
1,2-Diphenyl-4-n-butyl-4-hydroxymethyl-3,5-dioxopyrazolidine Hemisuccinate
4-butyl-4-(beta-carboxypropionyloxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione
SCHEMBL25810
BSPBio_000695
BSPBio_002327
KBioGR_000786
KBioSS_000801
MLS002153938
DivK1c_000171
SPECTRUM1501157
SPBio_000971
SPBio_002616
BPBio1_000765
CHEMBL1414320
HMS500I13
HY-B1079R
KBio1_000171
KBio2_000801
KBio2_003369
KBio2_005937
KBio3_001547
BRD5826
M02AA22
NINDS_000171
HMS1570C17
HMS1923I17
HMS2097C17
HMS2232E17
HMS3371A12
HMS3714C17
Pharmakon1600-01501157
BRD-5826
HY-B1079
Tox21_110615
Tox21_202352
Tox21_302778
CCG-40180
NSC757866
AKOS024374988
Tox21_110615_1
CS-4635
DB13232
4-{[(4-butyl-3,5-dioxo-1,2-diphenylpyrazolidin-4-yl)methyl]oxy}-4-oxobutanoic acid
IDI1_000171
NCGC00016799-02
NCGC00016799-03
NCGC00016799-04
NCGC00016799-05
NCGC00016799-06
NCGC00016799-08
NCGC00095261-01
NCGC00095261-02
NCGC00095261-03
NCGC00095261-04
NCGC00256470-01
NCGC00259901-01
MS-27855
SMR001233279
SBI-0051667.P002
DB-047228
AB00052229
NS00008152
D01289
F85232
AB00052229_08
AB00052229_09
Q7650623
SR-01000841241-2
SR-01000841241-3
BRD-K78815826-001-05-4
BRD-K78815826-001-08-8
BRD-K78815826-001-13-8
BRD-K78815826-001-14-6
Suxibuzone, European Pharmacopoeia (EP) Reference Standard
4-[(4-Butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methoxy]-4-oxobutanoic acid
4-Butyl-4-(.beta.-carboxypropionyl-oxymethyl)-1,2-diphenyl-3,5-pyrazolidinedione
248-477-6
Butanedioic acid, mono((4-butyl-3,5-dioxo-1,2-diphenyl-4-pyrazolidinyl)methyl) ester (9CI)
Solubility of 4-[(4-butyl-3,5-dioxo-1,2-diphenyl-pyrazolidin-4-yl)methoxy]-4-oxo-butanoic acid
The solubility of 4-[(4-butyl-3,5-dioxo-1,2-diphenyl-pyrazolidin-4-yl)methoxy]-4-oxo-butanoic acid (C19H20N2O3) is influenced by several factors, including its molecular structure and polarity. Here are some key points regarding its solubility:
In summary, while 4-[(4-butyl-3,5-dioxo-1,2-diphenyl-pyrazolidin-4-yl)methoxy]-4-oxo-butanoic acid shows potential for solubility in polar solvents, it is crucial to consider its structural components and the nature of the solvent for a comprehensive understanding. As the saying goes, "Like dissolves like", making solvent selection a critical factor for solubilizing this compound effectively.